There was no statistically significant difference in age, percentage of males, ECOG score, cancer treatment, D‐dimer, conduction disorder on ECG, decreased LVEF on TTE, Albumin/globulin, AST/ALT, LDL/HDL, time to the incidence of myocarditis, non‐cardiac immune‐related adverse events, past comorbidities, myocarditis treatment and mortality between the two groups (Table 4). This evidence concerns the gene GPT and myocarditis.